China News Online, November 6th (Yu Youzhao) The number of percutaneous coronary procedures (PCI) in China is increasing, and the improvement of its success rate and the prognosis of patients after surgery has attracted much attention.
Ge Junbo, academician of the Chinese Academy of Sciences, addressed in Shanghai on the 6th that Chinese and foreign medical technology companies that have reached strategic cooperation in the field of coronary interventional imaging can use their respective advantages to accelerate the implementation of the "precision PCI" concept under the guidance of intracavitary imaging, and bring patients' needs for healing Come to a more complete solution.
On the same day, the medical technology company Boston Scientific and the Chinese medical device innovation company Low Light Medical signed a strategic cooperation agreement. The two parties will give full play to their respective advantages in the field of coronary interventional endovascular imaging, such as technological innovation, industrial integration, and resource complementarity to further improve PCI The precision medical intracavitary imaging product system promotes the rapid coverage of domestic OCT products in the market, and empowers the transformation of local medical innovation achievements and industrialization upgrading and transformation.
"We will continue to actively promote open innovation and in-depth cooperation with local medical companies, promote the sinking of high-quality medical resources, improve the timeliness and accessibility of primary care, and help achieve a'healthy China'." Zhang Jun, President of Boston Scientific Greater China Say.
Founded in 2012, Low Light Medical is a high-tech enterprise incubated and supported by Xi’an Institute of Optics and Mechanics, Chinese Academy of Sciences.
They focus on the independent R&D and industrialization of high-end cardiovascular OCT systems and have achieved 49 authorized patents.
In July this year, the Low Light Medical "Cardiovascular Optical Coherence Tomography (OCT) System" was officially launched. This product has designed and developed a number of intelligent image analysis functions and applied artificial intelligence algorithms to improve the overall performance of the product's software and hardware.
Zhu Rui, chairman of Microlight Medical, said that the product has been tested in dozens of hospitals in Beijing, Shanghai, Tianjin, Harbin and other hospitals, with good clinical feedback.
They also maintain long-term and stable cooperation with well-known institutions such as Harvard University Medical School and Erasmus Medical Center in the Netherlands.
He revealed that the second-generation OCT system products are being developed. Compared with the first-generation products, a lot of original functions have been added, and it has entered the inspection stage.
Zhu Rui said that in the future, it will continue to base itself on independent core technologies and localized industrial advantages, strengthen cooperation between scientific and technological innovation and international institutions, so as to better connect the domestic and international markets, and help "Healthy China 2030".
As the founder of the Chinese Cardiovascular Doctor Innovation Club, Academician Ge Junbo said that strengthening international medical cooperation under the epidemic has become the focus of attention of all countries. The cooperation model of "technical innovation + resource complementarity" between China and foreign countries has opened up new ideas for many companies.
(Finish)